Japanese pharmaceutical company Ono Pharmaceutical has joined Cancer Research UK in a drug discovery alliance formed to accelerate the development of immunotherapy treatments.
The partnership announced on 27 March—which expands an existing alliance between Cancer Research UK and LifeArc formed in 2017—will identify targets for the development of antibody and small molecule therapeutics, the funder said.
Under the deal, Ono will have rights to license the discoveries of the alliance, and commercialise any resulting treatments with worldwide exclusive rights.
This article on Research Professional News is only available to Research Professional or Pivot-RP users.
Research Professional users can log in and view the article via this link
Pivot-RP users can log in and view the article via this link.